Graphen Medical

Drug development, genome analysis and proteogenomics pathway analysis for the future precision medicine and precision health.

 

Products and Projects

Consumer Services

Whole Genome Analysis

Graphen Personal Whole Genome Analytics System analyzes one's entire 6.4B genome with one single test. It provides risk likehood of 350+ diseases in 10 major categories and can provide life long updates as new relevant researches become available over time.

Gene Dynamic Detection

Graphen's Gene Dynamic Detection provides one's current status on 100+ diseases in the protein pathway. It uses genetic tracking to understand the trend of one's genetic performance and grasp the safe distance between you and the disease. It assesses specific disease risks, design precise gene probes and provide precise prevention and health risk managment strategies.

Co-Development

Drug Development

Graphen Atom presents a great opportunity to the biochemical and pharmaceutical industries by offering efficient access and understanding of vast amounts of chemical data, potentially improving the processes and outcomes of drug development.

Graphen has been working with major pharmaceutical companies for years to create novel AI and machine learning methods, pioneering the use of machine learning techniques such as using neural networks to help establish new molecules to be considered, better understand the biological effects of existing molecules.

Research Collaboration

Virus Mutation Monitoring

Graphen contributes to the worldwide community in the fight against the COVID-19 coronavirus by providing our expertise in genome analysis. Graphen analyzed the variants of each reported whole genome sequencing from more than 100 countries and regions to-date, and identified the mutations as they spread.

Large-Scale Medical Article Understanding

To help understand large volumes of complex and lengthy medical articles, Graphen invented two important mechanisms: Biomedical Literature Question-Answering Methodology and Citations Methodology. Utilizing AI technologies to read and understand tens of thousands of medical articles and reports efficiently.

Atom AI Tools powers Novel Medical Solutions

Based on Full-Brain Graphen Ardi platform and AI Medical Platform Graphen Atom, Graphen Medical products currently include:

  • Consumer Services: Consumer Whole Genome Disease Analysis, Gene Dynamic Detection, Personalized Precision Medicine, Personalized Health Prediction
  • AI Tools for Drug Development
  • Virus Mutation Surveillance
  • Large-Scale AI Medical Article Understanding
  • Together, they are paving a way towards future precision medicine and precision health.

    Graphen Medical approaches health care with the individual variability in genes, environment and lifestyle in mind.

    Built upon the next-gen Ardi AI Platform, Atom Medical utilizes Graph Database and Analytics, Auto Model Optimizer and Autonomous Learning in analysis, prediction, treatment and prevention.

    Image

    Consumer Services

    Congenital Me

    Graphen Whole Genome Analysis

    Do you want to know more about yourself? What does your blueprint say about your health and wellbeing? Graphen Personal Whole Genome Analytics System analyzes your entire 6.4B genome. It provides your risk likehood of 350+ diseases in 10 major categories.

    Today's Me

    Gene Dynamic Detection

    Graphen Proteome Analytics System provides you with your current status of wellbeing on 100+ diseases in the protein pathways. It gives you a graphical representation on what your protein variations have been impacting your body.

    Future Me

    Predictive Health Analysis

    Combining the genomic, proteomic, and environmental analysis, in conjunction with personal Electronic Medical Record, Graphen Atom helps you find what may come next, based on the pathway analysis. Let our analytic results help you towards a healthy life.

    Image

    AI Tools for Drug Development

    Graphen has been working with major pharmaceutical companies for years to create novel AI and machine learning methods, pioneering the use of machine learning techniques such as using neural networks to help establish new molecules to be considered, better understand the biological effects of existing molecules. Graphen uses techniques like active learning to guide the search, selection, and refinement of these molecules.

    Graphen has four stages to develop drugs:

  • Stage 1: Druggable Candidates Finding using Whole Genomic Analysis Tool and Signal Pathway Analysis Tool.
  • Stage 2: Candidates Preprocessing using Epitope/Paratope Site Prediction Tool, Protein Function Prediction Tool and Protein Structure Prediction Tool.
  • Stage 3: Small Molecular / Biosimilar Drug Development using ADME prediction Tool, Antibody - Antigen Selection Model Graph-Based Drug Target Affinity Prediction.
  • Stage 4: Precision Drug Development using mutated Protein Binding Energy prediction
  • Our drug development solution outperforms the best-known competitors in all tools except the protein structure prediction tool, which Graphen is outperformed by Google DeepMind.

    Image

    COVID-19 Live Monitoring

    Graphen is contributing to the worldwide community on the flight with the COVID-19 coronavirus by providing our expertise in genome analysis. Graphen analyzed the variants of each reported whole genome sequencing from more than 100 countries or regions to date and identified the mutations as they spread. With the help of Network Science analytics, we visualized how the virus propagated, mutated and spread throughout the world and has published our analysis with daily updates.

    By understanding the mutation of each virus and locating where those variants are in its near 30,000 genetic locations, Graphen can identify virus' evolution chain, as well as clusters. Such mutation and propagation patterns can help companies better identify targets for drug development, public health prediction on the spreading speed, or even predict the harmfulness of specific variants that may cause symptoms beyond those observed from the original strain.

    Graphen’s early warning at the end of September 2020 on the Intl. Symposium on COVID was about 2.5 months ahead of UK government’s warning. Our binding energy prediction model is proven better than the current leading state-of-the-art in predicting ΔΔG.

    Learn more about our work here.

    Image

    Speak to an expert today.